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osting by EAbstract Background and objectives: Tinea capitis is a common infection of the scalp and hair
shaft caused by dermatophyte fungi that mainly affects prepubescent children. Systemic therapy
is required for treatment and to prevent spread. The aim of present study was to assess the effect
of terbinaﬁne for Tinea capitis treatment in children.
Methods: Thirty Iranian pediatric patients with a clinical diagnosis of Tinea capitis were enrolled in
the study. The Study was conducted in a general and referral teaching hospital (Imam Medical Cen-
tre – Tehran, Iran) from 2006 to 2007. Eligible patients with less than 20 kg of body weight were
given 62.5 mg terbinaﬁne, and for patients between 20 and 40 kg the dose was 125 mg, on the ﬁrst
visit. All patients had the second clinical visit and second samples for microscopic study were taken.
For each patient, direct mycology test (KOH test) and mycological culture were carried out before
the study was started and after second, fourth, ﬁfth, sixth and eighth weeks. Probable drug’s adverse
effects were also recorded.
Results: Based on the results of mycological culture of patients’ lesions, Microsporum canis and
Trichophyton sheonlini were considered as major causes of Tinea capitis in these children. Out of
30 study patients, KOH test of 93% in the 5th week and 100% in the 6th week was negative. All
patients healed completely from signs of infection, after six weeks. Also, no severe side effects were
seen in any patients.
Conclusion: According to the results of this study, the use of terbinaﬁne is an effective therapy in
Iranian cases of Tinea capitis in children without severe side effects.
ª 2009 King Saud University. All rights reserved..ac.ir (A.M. Sabzghabaee).
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lsevier1. Introduction
Skin dryness can discourage colonization by microorganisms,
and the shedding of epidermal cells may inhibit many microbes
from permanent residence. Occlusion of the skin with nonpo-
rous materials can interfere with the skin’s barrier function
by increasing local temperature and hydration. When the pro-
tective mechanisms of the skin failed or be inhibited, cutaneous
244 A.M. Sabzghabaee et al.infection may occur (Hainer, 2003). Dermatophytes require
keratin for growth, so they are restricted to hair, nails, and
superﬁcial skin and these fungi do not infect mucosal surfaces.
Dermatophytoses are referred to as ‘‘tinea’’ infections. They
are also named for the body site involved.
Tinea capitis (ringworm) is widespread throughout the
world, and above all in Africa, Asia, South-eastern Europe
and even in UK it is one of the most frequent forms of dermat-
omycosis (Frieden and Howard, 1994). A community point
prevalence study from London suggested a disease prevalence
of about 2.5% with a carriage rate of between 12% and 47%
among schoolchildren (Hay et al., 1996). The disease rarely af-
fects mature patients (but in post-menopausal women) (Aste
et al., 1966) and is mostly found in children almost irrespective
of age or sex (Elewski, 1966). Scalp and hair shaft are the most
common sites of infection. Transmission is fostered by poor
hygiene and overcrowding, which may have a role in transmis-
sion of disease through contaminated hats, brushes, pillow-
cases, and other inanimate objects. After being shed, it
should be noted that affected hairs can harbor viable organ-
isms for more than one year after shedding (Hainer, 2003).
Irregular or well-demarcated alopecia and scaling are common
clinical features of ringworm. When swollen hairs fracture a
few millimeters from the scalp, ‘‘black dot’’ alopecia is pro-
duced. Boggy, sterile, inﬂammatory scalp mass due to a cell-
mediated immune response (kerion) and also occipital lym-
phadenopathy may be seen in Tinea scalp infection as well
(Hainer, 2003). In some cases, patients have symptoms and
clinical signs of minimal ringworm infection but they are still
mycologically positive and presumed capable of transmitting
infection.
Tinea capitis requires systemic treatment because generally,
topical antifungals are unable to sufﬁciently penetrate the hair
shaft to clear the infection and systemic therapy is usually indi-
cated. Furthermore, the use of topical antifungal treatment
alone may contribute to the creation of carriers (Fuller et al.,
2003). The only licensed treatment is oral Griseofulvin, the
most common approved drug for oral therapy. It is usually gi-
ven at a dose of 10 mg/kg for 6–8 weeks and in resistant cases,
longer treatment may be required at doses of up to 20–25 mg/
kg (Elewski, 1966). Due to long time course of therapy, it is
highly recommended to have a positive mycology result before
starting (Ali et al., 2007) and in more complicated cases of this
disease (patients with pustular Tinea capitis and kerion), use of
antifungal creams or shampoos while waiting for the mycology
results (to reduce the risk of progression) is indicated (Fuller
et al., 2001). Regarding the prevalence of ringworm in pediat-
ric patients, unfortunately the compliance with such a lengthy
treatment regimen is poor and lack of a suitable pediatric for-
mulation of griseofulvin (e.g. suspension) for this subpopula-
tion in many countries including Iran makes the efﬁcacy of
griseofulvine therapy much more complicated. Furthermore,
some patients do not respond to standard therapy and may re-
quire higher doses or prolonged durations. In a recent survey
of griseofulvin treatment of Tinea capitis in a practice setting,
approximately 40% of patients did not respond to the drug
and required additional treatment (Abdel-Rahman et al.,
1997). So, if an antifungal drug with sufﬁcient efﬁcacy on ring-
worm needs a shorter course of therapy and also has a more
convenient dosage regimen with an acceptable safety, it could
be considered as a real therapeutic rival for griseofulvin.Terbinaﬁne, which has an allylamine chemical structure,
has been developed as a new class of ergosterol biosynthetic
inhibitors that are functionally as well as chemically distinct
from the other major classes of ergosterol-inhibiting antifungal
agents (Ryder and Favre, 1997). The drug is highly effective
against dermatophytes in vivo and in vitro (Ghannoum and
Rice, 1999). In one review research, out of 21 studies with
1812 participants, the use of terbinaﬁne for four weeks and
griseofulvin for eight weeks showed similar efﬁcacy in three
studies involving 382 participants. So, newer treatments
including terbinaﬁne may be similar to griseofulvin in children
with tinea capitis caused by Trichophyton species. Also, be-
cause of its fungicidal action, it requires shorter treatment per-
iod than griseofulvin (Gonzalez et al., 2007). Allylamines act
by inhibiting early steps of ergosterol biosynthesis. This inhibi-
tion coincides with accumulation of the sterol precursor squa-
lene and the absence of any other sterol intermediate,
suggesting that allylamine inhibition of sterol synthesis occurs
at the point of squalene epoxidation, a reaction catalyzed by
squalene epoxidase (Ryder and Favre, 1997). Studies with iso-
lated squalene epoxidase indicate that it is the target for allyl-
amine activity (Ghannoum and Rice, 1999). Terbinaﬁne has a
considerable hepatic metabolism which may rise concern
about the pharmacogenetic differences of drug metabolism in
different populations and the safety of standard dosing regi-
men in genetically different populations (Ghannoum and Rice,
1999). The drug may also cause hepatotoxic effects on the liver
which increases the above-mentioned concern (Wickersham,
2009).
Many studies have evaluated the efﬁcacy of terbinaﬁne in
white Caucasian populations (some of them were sponsored
by the manufacturer of the original brand product of the drug)
(Fuller et al., 2001; Memisoglu et al., 1999; Haroon et al.,
1996; Kullavanijaya et al., 1997; Caceres-Rios et al., 2000;
Rademaker and Havill, 1998; Filho et al., 1998) but to knowl-
edge of authors, there is not enough reliable data on both
safety and efﬁcacy of the drug in Iranian pediatric patients
with ringworm. The aim of present study is to evaluate the
safety and efﬁcacy of terbinaﬁne in a pediatric Iranian cohort
of patients with Tinea capitis.
2. Methods
The study design was open label clinical trial which was con-
ducted in a general and referral teaching hospital afﬁliated
with Tehran University of Medical Sciences (Imam medical
centre, Tehran, Iran) from 2006 to 2007. All pediatric patients
(up to 12 years old) with clinical signs and symptoms of ery-
thema, scaling, hair loss and scalp itching who were diagnosed
for Tinea capitis by a registered dermatologist (PM) and by
laboratory conﬁrmation of primary diagnosis with a positive
test of potassium hydroxide (KOH) were considered eligible
for the study. During the study, patients with chronic or active
liver disease or any undiagnosed rise of hepatic marker en-
zymes (e.g. ALT&AST), complicated gastrointestinal disease,
concurrent seborrheic dermatitis, or other scalp conditions
such as scabies, psoriasis, head lice, or atopic dermatitis or
use of any oral/topical treatment for Tinea capitis in the past
2 weeks of therapy and also patients with signs and symptoms
of hypersensitivity to terbinaﬁne after the start of therapy were
excluded. Sampling was random using convenient sampling
Table 1 Reported side effects of Terbinaﬁne in study patients.
Side eﬀect % (number of cases)
Gastrointestinal upset 30 (9)
Itching 16.7 (5)
Skin rash 6.7 (2)
Headache 6.7 (2)
Fatigue 3.3 (1)
Anxiety 3.3 (1)
Hepatotoxicity 0 (0)
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inclusion criteria a research proﬁle including demographic
data (e.g. name, age, sex, and weight), location of infection
on scalp, duration of disease, previous therapy, baseline hepa-
tic enzymes (ALT/AST), result of KOH test and mycologic
culture result and drug’s probable adverse effects (gastrointes-
tinal upset, skin rash, itching, headache, fatigue or anxiety)
was completed before the start of therapy, and after second,
fourth, ﬁfth, sixth and eighth weeks. Eligible patients with less
than 20 kg of body weight were given 62.5 mg (1/4 of Lamisil
250 mg tablet) and if the patients total body weight was be-
tween 20 and 40 kg, the dose was 125 mg (1/2 of Lamisil
250 mg tablet) on the ﬁrst visit. After two weeks, all patients
had a second clinical visit and a second sample for microscopic
study was taken. Patients were advised to take the prescribed
dose of terbinaﬁne tablet before meal and contact the attend-
ing physician if they felt any unexpected effects such as gastro-
intestinal upset, skin rash, itching, headache, fatigue or
anxiety. If therapy was not complete, another course of a 14-
day treatment with terbinaﬁne was tried and if only clinical
signs were not completely cured despite the negative results
of mycological studies, the course of therapy was extended
only for one week and patients were called for a third visit.
All eligible patients and their parents or guardians as well
were interviewed by one of the investigators for explaining
the whole study and were also completely free to let their child
be included in the study or not. All the included subjects also
had a written informed consent form which was signed freely
after the interview by their guardians and they could ask for
exclusion of their child from the study without any fear of
loosing their routine medical care. The study was performed
in accordance with guidelines laid down by the Declaration
of Helsinki II and also by Tehran declaration for ethics in hu-
man researches. The study protocol was approved by the
board of human studies in Deputy of Research at Tehran Uni-
versity of Medical Sciences. It should be mentioned that de-
spite the fulﬁllment of all ethical issues in this study, here in
Middle East, due to some cultural reasons, taking a signed in-
formed consent form like that taken in similar routine clinical
trials in the west is very difﬁcult.
Using NCSS-PASS (Jerry Hintze, Utah, 2004) the mini-
mum patient number for at least an 80% of total cure 4 weeks
of therapy (a= 0.05) and for a power of 80%, was calculated
as 30 patients. Providing about 100% of dropping out patients
(as they may meet the exclusion criteria or may not follow the
long course of therapy) the total patients number needed for
the study was at least 60. v2, Mann–Whitney’s U-test, Stu-
dent’s t-test and paired t-test were performed for statistical
analysis using SPSS 11 statistical software.0
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Figure 1 Response rate of study patients to terbinaﬁne.3. Results
During the 14 months of study, 60 patients met the inclusion
criteria from which 30 patients (17 male and 13 female) had
completed the full course of study (8 weeks). One patient was
infant (<2 years), 8 were between 2 and 6 and most of the oth-
ers (Aste and Pau, 2004) were more than 6 and less than 12
years old. 46.6% (Memisoglu et al., 1999) patients had ring-
worm lesion in the upper area of scalp, 20% (Fuller et al.,
2003) in the back, 26.6% (Fuller et al., 2001) in right up and left
up, and 6.6% (Frieden and Howard, 1994) in the frontal part.Regarding the traditional classiﬁcation of Tinea capitis based
on KOH test, 70% (Aste and Pau, 2004) of patients had endo-
trix form and the rest of them had favus lesions. Twenty-two
patients had no previous medical treatment before the study,
while 4 had 6 weeks course of griseofulvin, 2 had oral tablet
of ketokonazole and 2 had topical clotrimazole at least 14 days
before the inclusion. The result of mycologic culture of the
study patients lesions was as follows: Microsporum canis
(46.7%), Trichophyton sheonlini (30%), Trichophyton verruco-
sum (10%), Microsporum gypsium (6.7%) and Trichophyton
tonsurans (6.7%). No case of hepatotoxicity (rise of ALT/
AST to more than ﬁve times of baseline) was reported
(Table 1).
4. Discussion
Terbinaﬁne is a member of a new family of antifungal drugs,
Allylamines. In spite of Azoles which are fungi growth inhibi-
tors, Terbinaﬁne is a real fungicide. Terbinaﬁne not only acts
by inhibiting ergos-terol synthesize but also by accumulating
squalene as well, leads to fungi destruction (Abdel-Rahman
et al., 1997). Concerning therapy rate and high healing per-
centage even until 3 weeks after quitting drug intake, active
drug concentration is high in stratum corneum and remains
there for a long time after ﬁnishing therapy period (Faerge-
mann et al., 1991). Thirty patients who were about 7 years
old have participated in this study. Most of the patients suf-
fered from itching, scaling and hair loss while the affected site
was on the top and frontal part of the scalp. The infection his-
tory was from one week to 2 years.
246 A.M. Sabzghabaee et al.Out of 30 study patients, the direct mycology examination
(KOH test) of 13.3% of patients in the second week, 90% in
the fourth, 93.3% in the ﬁfth and 100% in the sixth week
was negative. Also, 0% of the patients in the second week,
60% in the fourth, 65% in the ﬁfth, 80% in the sixth and
100% in the eighth week revealed clinical healing (Fig. 1).
All patients healed completely from scaling, itching and hair
loss after six weeks. Only scar, partial inﬂammation and bleed-
ing continued in 4 patients after 2 weeks, which were healed
until the end of therapy period. Concerning complete therapy
(clinical healing and negative culture), none of the patients
healed until the 5th week but 80% healed in the 6th, 92% in
the 8th and 100% in the 12th week completely.
In one review research, out of 21 studies with 1812 partici-
pants, terbinaﬁne given for four weeks and griseofulvin given
for eight weeks showed similar efﬁcacy in three studies involv-
ing 382 participants. So, newer treatments including terbinaﬁne
may be similar to griseofulvin in children with Tinea capitis
caused by Trichophyton species. Also, because of its fungicidal
action, it requires shorter treatment period than griseofulvin.
In the same study which evaluated the effectiveness and tol-
erability of terbinaﬁne treatment for a period of 12 weeks in Ti-
nea capitis caused by Microsporum canis, out of 26 patients,
clinical and mycological healing was achieved in 22 patients
(84.6%). Tolerability was excellent and in no cases could side
effects be felt (Aste and Pau, 2004). So, concerning terbinaﬁne
efﬁcacy, the results of this study are the same as those of the
present study. In another study on 176 patients with a clinical
diagnosis of Tinea capitis treated with oral terbinaﬁne for 1,
2 and 4 weeks, effective treatment was achieved in 56%, 69%
and 65% of patients, respectively. According to these results,
2 weeks of terbinaﬁne therapy appears to be the optimal treat-
ment duration for patients with Tinea capitis (Friedlander
et al., 2002). Although the results of the current study indicate
that two weeks of terbinaﬁne therapy is not sufﬁcient for Tinea
capitis treatment, complete healing is achieved after 12 weeks.
In the present study referring to questions asked to patients
in special data forms, no severe life-threatening side effects were
seen in patients. According to previous studies on side effects of
Terbinaﬁne, 5% of the patients suffered from gastrointestinal
complications such as nausea and vomiting and 3% suffered
from urticaria. Non-speciﬁc side effects such as headache and
taste disorder were also reported, which could not be felt after
quitting drug intake (Friedlander et al., 2002; Villars and Jones,
1989). However, in some similar studies, mentioned side effects
have not been seen in patients, which is the same as current
study (Jones, 1995; Nejjam et al., 1995; Chang et al., 2007).
According to the results of this study, terbinaﬁne proved to
be effective in cases of Tinea capitis in children without show-
ing severe side effects.
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